Audentes Therapeutics raises $65 million in series C financing
Audentes Therapeutics announced the closing of an oversubscribed $65 million Series C financing. The financing was co-led by existing investor Sofinnova Ventures and new investor Redmile Group. Proceeds will be primarily used to advance the company’s three lead development programs. October 13, 2015